

March 11, 2002

1900 K STREET, N.W. WASHINGTON, D.C. 20006-1109

TEL 202 • 955 • 1500 FAX 202 • 778 • 2201

DI RECEIVED

MAR 15 2002

TECH CENTER 1600/2800

In re Patent Application of:

Attorney Docket No.:

59866.000002

Mads N. HOLTEN-ANDERSEN et al.

Application No.: 09/546,573

Group Art Unit: 1642

Filed: April 10, 2000

Examiner:

RAWLINGS, S.

Title:

TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1)

AS A CANCER MARKER

Commissioner for Patents Washington, DC 20231

Transmitted herewith is an amendment in the above-identified application. Fees have been calculated as shown below:

		CLA	IMS AS AMENDE	D	W		
		Claims Remaining After Amendment	Highest Number Previously Paid For	Extra	Rate Large Entity Small Entity		Amount
Number of Claims in Excess of 20		35	37	0	\$ 18.00	\$ 9.00	\$ 0.00
Independent Claims in Excess of 3		9	9	0	\$ 84.00	\$ 42.00	\$ 0.00
First Presentation of Multiple Dependent Claims			\$ 280.00	\$ 140.00	\$ 0.00		
Extension Fee: a)	One Month				\$ 110.00	\$ 55.00	\$55.00
b)	Two Month	s			\$ 400.00	\$ 200.00	\$ 0.00
c)	Three Months			\$ 920.00	\$ 460.00	\$ 0.00	
d)	Four Month	S.			\$1440.00	\$ 720.00	\$ 0.00
e)	Five Month	S			\$1960.00	\$ 980.00	\$ 0.00
Other:							\$ 0.00
TOTAL FEE DUE							\$55.00

No additional fee is required. A check in the amount of \$ 55.00 is attached. Charge \$ to Deposit Account No. 50-0206. Charge any additional fees or credit any overpayment to Deposit Account No. 50-0206.	
Small Entity Status Claim: is hereby requested. is of record in this application. Respectfully submitted,	,

Registration No. 28.562 ATLANTA AUSTIN BANGKOK BRUSSELS CHARLOTTE DALLAS HONG KNOXVILLE LONDON MCLEAN MIAMI NEW YORK NORFOLK RALEIGH RICHMOND WARSAW WASHINGTON

WASHINGTON 276815v1

Copied 1701 100309/2 on 01-03-2004

Attorney Docket No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mads N. HOLTEN-ANDERSEN et al.

Group Art Unit: 164

Application No.: 09/546,573

RECEIVED CENTER 1600/2900 Examiner: RAWLINGS,

Filed: April 10, 2000

For:

TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES

TYPE-1 (TIMP-1) AS A CANCER MARKER

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents Washington, DC 20231

Sir:

Responsive to the Office Action of November 9, 2001, a one month extension of time having been obtained, please amend the patent application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

I. On page 27, lines 1 - 3, please delete the paragraph and replace it with following replacement paragraph:

The median TIMP-1 level in plasma from healthy donors was 88.6 µg/L with a range of 51.0-156.2 $\mu g/L$. There was a highly significant statistical difference in the total plasma TIMP-1 values between the colorectal cancer patients and the healthy blood donors.

)3/14/2002 ADSMAN1 00000108 09546573

)1 FC:215

55.00 OP